Sab Biotherapeutics, Inc. · NASDAQ:SABS
Sab Biotherapeutics — Investor Presentation (2026)
32 slides from Sab Biotherapeutics's investor presentation, 2026
Slide 1: Targeting T1D, Modifying Disease, Moving Beyond Insulin
Targeting T1D Modifying Disease Moving Beyond Insulin Corporate Presentation Q3 2026 © 2026 SAB BIOTHERAPEUTICS, INC.
Slide 2: Forward-Looking Statements
Forward-Looking Statements The material in this presentation has been prepared by SAB Biotherapeutics, Inc., doing business as SAB BIO (“SAB”) and is general background information about SAB’s activities current as of the date of this presentation. This information is given in summary form and is no
Slide 3: Transforming Treatment for People Living with Autoimmune Diseases
Transforming Treatment for People Living with Autoimmune Diseases through a Unique Disease-modifying Therapy At SAB BIO, our mission is to dramatically redefine what it means to be diagnosed with Type 1 Diabetes by developing a medicine to change the course of disease, not just treat symptoms 3
Slide 4: SAB BIO Investment Highlights
SAB BIO Investment Highlights Potential for Significant Value Creation and Patient Impact Leading Clinical-Stage Company Focused on Autoimmune Type 1 Diabetes SAB-142, our lead product candidate, is a potentially best-in-class, disease-modifying therapy with a de-risked REDEFINING T1D mechanism of a
Slide 5: SAB-142: Potential Disease-modifying Immunotherapy for Type 1 Diabetes
SAB-142: Potential Disease-modifying Immunotherapy Being Developed to Delay the Onset and Progression of Type 1 Diabetes SAB-142 is a multi-specific, fully human anti-thymocyte globulin (hATG) disease-modifying immunotherapy to delay the onset and progression of T1D Goal: develop a T1D therapy that
Slide 6: SAB-142 Manufactured Using Fully Human IgG Platform
SAB-142 is Manufactured Using our Fully Human Immunoglobulin G (hIgG) to Treat and Prevent Autoimmune Disorders SAB has a proprietary platform that can produce targeted, fully human, multi-specific antibodies without the need for human donors through its Tc Bovine platform Upstream at SAB’s Biosecur
Slide 7: Significant Unmet Need in Type 1 Diabetes
Significant Unmet Need in Type 1 Diabetes An evolving treatment landscape with a regulatory pathway informed by Tzield Stage 2 (Delay Onset) Market Stage 3 (Newly Diagnosed) Market 14.7M People with T1D globally 500,000 Patients WW by 20403 Diagnosed Annually2 Approved in Stage 2 patients to delay t
Slide 8: SAB-142: A Clinically Validated De-risked Mechanism of Action
SAB-142: A Clinically Validated De-risked Mechanism of Action rATG has been tested across multiple studies in T1D patients SAB-142: hATG tested in Phase 1 (HUMAN Study) 2013 2018 3Q 2025 2025 – 2026 rATG Tested rATG Tested rATG Tested SAB-142 tested in Academic Setting in Academic Setting in Academi
Slide 9: Rabbit ATG: De-Risked Mechanism of Action (TN-19)
TN-19 Rabbit ATG: De-Risked Mechanism of Action TN-19: Low-Dose rATG* Preserved Decline in C-peptide AUC Mean HbA1c Over Time C-peptide in New Onset T1D 1 and 2 Years Over Time by Treatment Group by Treatment Group Post Treatment ATG Only – Mean & 95% CI ATG Only – Mean & 95% CI Placebo – Mean & 95%
Slide 10: SAB-142 Phase 1 Data Demonstrated Encouraging Efficacy Signals
SAB-142’s Phase 1 Data Demonstrated Encouraging Phase 1: HUMAN* Trial Study Design Efficacy Signals with Clinically Validated, Multi-specific Randomized, double-blind, placebo-controlled, MOA with Sustained Immunomodulation single- and multiple- ascending dose, adaptive design clinical study Encoura
Slide 11: Complete Phase 1 Safety Data Support Outpatient Dosing
Complete Phase 1 Safety Data Support Outpatient Dosing and Chronic Treatment Potential Phase 1 data confirmed advancement into a registrational Phase 2b study in newly HV and T1D diagnosed adult, adolescents, and pediatric T1D patients (age 5-40) Key Safety Outcomes Mean Absolute Lymphocytes ± SEM N
Slide 12: SAB-142 Demonstrates Comparable MOA to rATG
SAB-142 Demonstrates a Comparable MOA to rATG, including Induction of Key T-cell Exhaustion Markers that have been Correlated with C-peptide Preservation in Prior rATG Studies HV 1 Treg preservation 2 Increase in CD4 exhaustion rATG Published Data: Responders to low-dose ATG induce CD4+ T-cell Treg
Slide 13: SAB-142 Induces Operational Tolerance via Exhaustion Markers
SAB-142 Induces Operational Tolerance as Indicated by Single and Dual-Exhaustion Markers HV SAB-142 Phase 1 Top-Line Data: 1 SAB-142 CD4+ T Conv Cell Single Exhaustion Markers 2 SAB-142 CD4+ T conv Cell Dual Exhaustion Markers Relative TIGIT+ Tconv Cells ± SEM Tconv Median % Change from Baseline SAB
Slide 14: Adult Established T1D Cohort: C-Peptide Responses
Adult Established T1D Cohort: C-Peptide Responses Established T1D MMTT C-Peptide Mean AUC ± SEM C-peptide demonstrated preservation over time SAB-142 Placebo in the SAB-142 T1D 0.6 0.3 2.5 mg/kg cohort vs. study placebo and TN19 TN19 Placebo Cohort1 placebo cohort1 0.5 0.2 Change from baseline in me
Slide 15: C-Peptide Responses and T Cell Exhaustion
C-Peptide Responses and T Cell Exhaustion Super Responders vs. Responder Established T1D & HV In SAB-142 T1D cohort, 3 of the 4 participants MMTT C-Peptide Mean AUC ± SEM Relative TIGIT+ Tconv Cells ± SEM exhibited mean C- Placebo SAB-142 SAB-142 peptide values consistent 0.3 Super Responders 160 Pl
Slide 16: Adult Established T1D Cohort: CGM Time in Range
Adult Established T1D Cohort: Continuous Glucose Monitoring (CGM) Time in Range Established T1D Participants receiving CGM Mean Time in Range SAB-142 (2.5 mg/kg) demonstrated an TIR TIR 73% 85% increase in mean TIR from 73% at baseline to TVAR TAR 85% at Day 120 TIR TBR SAB-142 effects on TVBR glyce
Slide 17: SAB-142: Potential for Broadest Use with Superior Safety and Convenience
SAB-142: Potential for Broadest Use with Superior Safety, Efficacy, and Patient Convenience in a Broad Age Range of T1D Patients* *** SAB-142 CD4+ exhaustion signature SAB-142 exhibits Treg preservation multi-specific T-cell exhaustion profile No sustained lymphodepletion (Tconv and/or Tregs) and Tr
Slide 18: SAFEGUARD: Global Phase 2b in Stage 3 Type 1 Diabetes
SAFEGUARD: Multicenter, Global Phase 2b for SAB-142 in Stage 3 Type 1 Diabetes Patients Global study initiated with topline results expected 2H 2027 Phase 2b Study SAFety and Efficacy of human anti-thymocyte immunoGlobUlin SAB-142 ARresting progression of United States Europe United Kingdom Australi
Slide 19: PRISE-hATG: Global Phase 3 in Stage 3 Type 1 Diabetes
PRISE-hATG: Multicenter, Global Phase 3 for SAB-142 in Stage 3 New, Recent and Extended Onset Type 1 Diabetes Patients PRISE-hATG Phase 3 Study Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation United States Europe United Kingdom in New, Recent, and Extended Ons
Slide 20: Strong Balance Sheet with Committed Strategic Partners
Strong Balance Sheet with Committed Strategic Partners Financial Snapshot: Recent Financings Fully Cash* Cash Runway* Fund Phase 2b SAFEGUARD $208M Through 2028 Study and Pre-Commercial Activities Potential for an additional $284 million if milestone-based warrants from July 2025 Key Clinical and St
Slide 21: Focused on T1D with Potential to Advance in Other Autoimmune Diseases
Focused on T1D with Potential to Advance in Other Autoimmune Diseases Preclinical Phase 1 Phase 2 Phase 3 Milestones: Type 1 Diabetes Q4’25: SAFEGUARD initiated Q1’26: Part A enrollment Delaying progression in new onset T1D patients (Stage 3) SAFEGUARD: Registrational Phase 2b completed; Part B init
Slide 22: Significant Catalysts Expected in 2026 and 2027
Significant Catalysts Expected in 2026 and 2027 2H 2025: Q4 2026: Phase 2b SAFEGUARD Phase 2b SAFEGUARD initiation enrollment completion Q2 2025: Q4 2025: 2H 2026: 2H 2027: SAFEGUARD Dosed first patient in the Phase 3 PRISE-hATG trial Phase 2b SAFEGUARD Type B FDA meeting SAFEGUARD trial first patie
Slide 23: SAB BIO Investment Highlights
SAB BIO Investment Highlights Potential for Significant Value Creation and Patient Impact Leading Clinical-Stage Company Focused on Autoimmune Type 1 Diabetes SAB-142, our lead product candidate, is a potentially best-in-class, disease-modifying therapy with a de-risked REDEFINING T1D mechanism of a
Slide 24: Thank You
THANK YOU Targeting T1D Modifying Disease Moving Beyond Insulin © 2026 SAB BIOTHERAPEUTICS, INC.
Slide 25: Appendix
Appendix
Slide 26: T1D Occurs in Progressive Stages
T1D Occurs in 3 Progressive Stages Identified by the Presence of Multiple Autoantibodies and Increasing Glycemic Levels T1D is associated with serious long-term complications, including diabetic nephropathy, neuropathy, and retinopathy, as SAB-142, currently in Phase 2b, well as increased risk of ca
Slide 27: MELD-ATG: Rabbit ATG De-Risked Mechanism of Action
MELD-ATG Rabbit ATG: De-Risked Mechanism of Action ATG is the only mechanism of action that has consistently MELD-ATG: Minimal Effective Low Dose of reproduced clinical data demonstrating preservation of rATG* Preserved C-peptide in New Onset T1D 1 Year Post Treatment C-peptide and improvements in g
Slide 28: Phase 1 Adult Established T1D Cohort: Baseline Characteristics
Phase 1 Adult Established T1D Cohort: Baseline Characteristics All study participants met SAFEGUARD inclusion criteria related to residual beta cell Established T1D function and at least one T1D autoantibody at baseline SAB-142 2.5 mg/kg Placebo T1D (n=4) T1D (n=2)* Age range Age range(mean) (mean)
Slide 29: Adult Established T1D Cohort: Total Exogenous Insulin Use
Adult Established T1D Cohort: Total Exogenous Insulin Use Established T1D Improvement in glycemic control was not Mean Total Insulin Use Per Day ± SEM associated with SAB-142 increases in exogenous Placebo insulin use 0.5 2.5 mg/kg Mean Change from Baseline (IU/day/kg) 0.4 Phase 1 study participants
Slide 30: SAB-142 Offers Distinct Advantages Over rATG
SAB-142 Offers Distinct Advantages Over rATG SAB-142 / hATG DISADVANTAGES Our Solution: Mechanism of Action: SAB-142 is a human alternative Majority of patients No risk of serum sickness due to rATG (Thymoglobulin) develop grade 3 to fully human product. Enables serum sickness opportunity to safely
Slide 31: SAB-142: The Next Generation of Beta Cell Guardians
SAB-142: The Next Generation of Beta Cell Guardians Sustained Immunomodulation without Lymphodepletion Pharmacodynamic Profile of SAB-142: Activation Phase Reprogramming Phase Sustained Immunomodulation T-Cell Exhaustion SAB-142 Dosing Signature Cytokines Activated Tregs Memory Shift Lymphocytes Mec
Slide 32: Thymoglobulin's Therapeutic and Dosing Profile vs Tzield in Stage 3 T1D
Thymoglobulin’s Therapeutic and Dosing Profile is Superior to Tzield in Stage 3 T1D Patients* PHASE 3 (PROTECT) DATA PHASE 2 TN-19 and MELD DATA ADVANTAGES Primary end point of C-peptide levels Primary end point of C-peptide AUC Statistically significant on C- C-peptide met at Month 18 met at Month